Madrigal Pharmaceuticals(DE:YDO1)
€393.90+11.50 (+3.01%)
DE:YDO1
Madrigal Pharmaceuticals stock forecast
€393.90
At close:+11.50 (+3.01%)
Madrigal Pharmaceuticals (YDO1) Stock Forecast & Price Target
1 Followers
YDO1 Analyst Ratings
Strong Buy
9Buy1Hold0Sell
Based on 10 analysts giving stock ratings to Madrigal Pharmaceuticals in the past 3 months
YDO1 Stock 12 Month Forecast
Average Price Target
€630.01▲(59.94% Upside)Based on 10 Wall Street analysts offering 12 month price targets for Madrigal Pharmaceuticals in the last 3 months. The average price target is EUR 630.01 with a high forecast of EUR 866.93 and a low forecast of EUR 431.66. The average price target represents a 59.94% change from the last price of EUR 393.90.
Past 12 Months12 Month ForecastJan2026Oct2026
High€866.93
Average€630.01
Low€431.66
Highest Price TargetHighest€866.93Average Price Target€630.01Lowest Price TargetLowest€431.66
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Ananda Ghosh | H.C. Wainwright | €558.73 | buy | 41.85%Upside | Reiterated | 11/12/26 | ||
| Jason Zemansky | Bank of America Securities | €431.66 | hold | 9.59%Upside | Reiterated | 11/09/26 | ||
| Eric Joseph | Citi | €653.36→€684.90 | buy | 73.88%Upside | Reiterated | 11/04/26 | ||
| Eliana Merle | Barclays | €866.93 | buy | 120.09%Upside | Reiterated | 11/04/26 | ||
| Sadia Rahman | Wells Fargo | €617.31 | buy | 56.72%Upside | Assigned | 11/04/26 | ||
| Edward Nash | Canaccord Genuity | €551.52→€570.45 | buy | 44.82%Upside | Reiterated | 11/04/26 | ||
| Srikripa Devarakonda | Truist Financial | €638.94→€669.58 | buy | 69.99%Upside | Reiterated | 11/04/26 | ||
 Unknown AnalystNot Ranked | B. Riley Securities | €603.79 | buy | 53.29%Upside | Reiterated | 10/29/26 | ||
| Ashwani Verma | UBS | €602.89→€662.37 | buy | 68.16%Upside | Reiterated | 10/15/26 | ||
| Andrea Newkirk | Goldman Sachs | €634.43 | buy | 61.06%Upside | Initiated | 09/24/26 | ||
| Andy Chen | Wolfe Research | €545.21 | buy | 38.41%Upside | Upgraded | 08/04/26 | ||
| Ritu Baral | TD Cowen | €580.36 | buy | 47.34%Upside | Reiterated | 07/30/26 | ||
| Jonathan Wolleben | Citizens JMP | €664.17→€665.97 | buy | 69.07%Upside | Reiterated | 07/17/26 | ||
| Unknown AnalystNot Ranked | Jefferies | €540.71 | buy | 37.27%Upside | Reiterated | 06/30/26 | ||
| Yasmeen Rahimi | Piper Sandler | €811.06 | buy | 105.91%Upside | Reiterated | 06/29/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Ananda GhoshH.C. Wainwright | BuyReiterated€558.73 | 11/12/26 | 41.85%Upside | ||
| Jason ZemanskyBank of America Securities | HoldReiterated€431.66 | 11/09/26 | 9.59%Upside | ||
| Eric JosephCiti | BuyReiterated€653.36→€684.90 | 11/04/26 | 73.88%Upside | ||
| Eliana MerleBarclays | BuyReiterated€866.93 | 11/04/26 | 120.09%Upside | ||
| Sadia RahmanWells Fargo | BuyAssigned€617.31 | 11/04/26 | 56.72%Upside | ||
| Edward NashCanaccord Genuity | BuyReiterated€551.52→€570.45 | 11/04/26 | 44.82%Upside | ||
| Srikripa DevarakondaTruist Financial | BuyReiterated€638.94→€669.58 | 11/04/26 | 69.99%Upside | ||
| Unknown AnalystB. Riley SecuritiesNot Ranked | BuyReiterated€603.79 | 10/29/26 | 53.29%Upside | ||
| Ashwani VermaUBS | BuyReiterated€602.89→€662.37 | 10/15/26 | 68.16%Upside | ||
| Andrea NewkirkGoldman Sachs | BuyInitiated€634.43 | 09/24/26 | 61.06%Upside | ||
| Andy ChenWolfe Research | BuyUpgraded€545.21 | 08/04/26 | 38.41%Upside | ||
| Ritu BaralTD Cowen | BuyReiterated€580.36 | 07/30/26 | 47.34%Upside | ||
| Jonathan WollebenCitizens JMP | BuyReiterated€664.17→€665.97 | 07/17/26 | 69.07%Upside | ||
| Unknown AnalystJefferiesNot Ranked | BuyReiterated€540.71 | 06/30/26 | 37.27%Upside | ||
| Yasmeen RahimiPiper Sandler | BuyReiterated€811.06 | 06/29/26 | 105.91%Upside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Madrigal Pharmaceuticals
3 Months
Success Rate8/13 ratings generated profit
62%
Average Return
+9.54%
Copying Yasmeen Rahimi's trades and holding each position for 3 Months would result in 61.54% of your transactions generating a profit, with an average return of +9.54% per trade.
1 Year
Success Rate17/22 ratings generated profit
77%
Average Return
+60.58%
Copying Jay Olson's trades and holding each position for 1 Year would result in 77.27% of your transactions generating a profit, with an average return of +60.58% per trade.
2 Years
Success Rate30/34 ratings generated profit
88%
Average Return
+93.28%
Copying Jonathan Wolleben's trades and holding each position for 2 Years would result in 88.24% of your transactions generating a profit, with an average return of +93.28% per trade.
YDO1 Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 4 | 5 | 10 |
| Buy | 19 | 12 | 13 | 7 | 6 |
| Hold | 5 | 4 | 3 | 1 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 29 | 21 | 20 | 13 | 19 |
In the current month, YDO1 has received 16 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. YDO1 average Analyst price target in the past 3 months is 630.01.
YDO1 Financial Forecast
High€3.21
Consensus€1.28
Low€-0.09
YDO1 Earnings Forecast
Next quarter’s earnings estimate for YDO1 is EUR 1.28 with a range of -EUR 0.09 to EUR 3.21. The previous quarter’s EPS was EUR 1.64. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High€450M
Consensus€427M
Low€414M
YDO1 Sales Forecast
Next quarter’s sales forecast for YDO1 is EUR 427.10M with a range of EUR 413.75M to EUR 450.36M. The previous quarter’s sales results were EUR 386.14M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
YDO1 Stock Forecast FAQ
What is DE:YDO1’s average 12-month price target, according to analysts?
Based on analyst ratings, Madrigal Pharmaceuticals’s 12-month average price target is €630.01.
What is DE:YDO1’s upside potential, based on the analysts’ average price target?
Madrigal Pharmaceuticals has 59.94% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Madrigal Pharmaceuticals a Buy, Sell or Hold?
Madrigal Pharmaceuticals has a consensus rating of Strong Buy, which is based on 9 buy ratings, 1 hold ratings and 0 sell ratings.
What is Madrigal Pharmaceuticals’s share price target?
The average share price target for Madrigal Pharmaceuticals is €630.01. This is based on 10 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €866.93, and the lowest forecast is €431.66. The average share price target represents a 59.94% increase from the current price of €393.9.
What do analysts say about Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Street analysts.
How can I buy shares of Madrigal Pharmaceuticals?
To buy shares of DE:YDO1, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
